Fortunately, there is an overlap in risk factor therapies so that antihypertensive renin angiotensin system blocking therapies including mineralocorticoid receptor antagonists (MRAs) also prevent CKD progression and SGLT2 inhibitors have pleiotropic effects broadly reducing risk of cardiorenal events [5, 23–26]. The gene discussed is SLC5A2; the disease is chronic kidney disease.